These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38444612)

  • 1. Thrombosis in patients with immune thrombocytopenia: incidence, risk, and clinical outcomes.
    Goncalves I; Lewis C; Grainger B; Dring R; Lee N; Pasricha SR; Szer J; Mason K
    Res Pract Thromb Haemost; 2024 Jan; 8(1):102342. PubMed ID: 38444612
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Thromboembolism in patients with immune thrombocytopenia (ITP): a meta-analysis of observational studies.
    Langeberg WJ; Schoonen WM; Eisen M; Gamelin L; Stryker S
    Int J Hematol; 2016 Jun; 103(6):655-64. PubMed ID: 27084254
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of risk factors on the occurrence of arterial thrombosis and venous thromboembolism in adults with primary immune thrombocytopenia - Results from two nationwide cohorts.
    Ekstrand C; Linder M; Baricault B; Lafaurie M; Sailler L; Lapeyre-Mestre M; Kieler H; Moulis G; Bahmanyar S
    Thromb Res; 2019 Jun; 178():124-131. PubMed ID: 31026663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.
    Ruggeri M; Tosetto A; Palandri F; Polverelli N; Mazzucconi MG; Santoro C; Gaidano G; Lunghi M; Zaja F; De Stefano V; Sartori R; Fazi P; Rodeghiero F;
    J Thromb Haemost; 2014 Aug; 12(8):1266-73. PubMed ID: 24942752
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment patterns and outcomes of second-line rituximab and thrombopoietin receptor agonists in adult immune thrombocytopenia: A Canadian retrospective cohort study.
    Podstawka J; Wall E; Bolster L; Patterson JM; Goodyear MD; Rydz N; Sun HL
    Thromb Res; 2022 Dec; 220():5-11. PubMed ID: 36257098
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E; Moulis G; Mahévas M; Guy C; Lioger B; Durieu I; Hunault M; Ramanantsoa M; Royer B; Default A; Pérault-Pochat MC; Moachon L; Bernard N; Bardy G; Jonville-Bera AP; Geniaux H; Godeau B; Cathébras P
    Rev Med Interne; 2017 Mar; 38(3):167-175. PubMed ID: 27793553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risk of thrombosis with thrombopoietin receptor agonists for ITP patients: A systematic review and meta-analysis.
    Tjepkema M; Amini S; Schipperus M
    Crit Rev Oncol Hematol; 2022 Mar; 171():103581. PubMed ID: 35007700
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors of hospitalisation for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments: a French nationwide cohort study.
    Lafaurie M; Maquet J; Baricault B; Ekstrand C; Christiansen CF; Linder M; Bahmanyar S; Nørgaard M; Sailler L; Lapeyre-Mestre M; Sommet A; Moulis G
    Br J Haematol; 2021 Nov; 195(3):456-465. PubMed ID: 34386974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adult immune thrombocytopenia and thrombopoietin receptor agonist: Ten years later].
    Ebbo M; Rivière E; Godeau B
    Rev Med Interne; 2021 Jan; 42(1):38-45. PubMed ID: 32712041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics, outcome, and response to therapy of multirefractory chronic immune thrombocytopenia.
    Mahévas M; Gerfaud-Valentin M; Moulis G; Terriou L; Audia S; Guenin S; Le Guenno G; Salles G; Lambotte O; Limal N; Viallard JF; Cheze S; Tomowiak C; Royer B; Neel A; Debouverie O; Hot A; Durieu I; Perlat A; Cliquennois M; Deteix C; Michel M; Godeau B
    Blood; 2016 Sep; 128(12):1625-30. PubMed ID: 27354722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Characteristics, risk factors and management of venous thromboembolism in immune thrombocytopenia: a retrospective multicentre study.
    Le Guenno G; Guieze R; Audia S; Khellaf M; Michel M; Bonnotte B; Ruivard M; Godeau B
    Intern Med J; 2019 Sep; 49(9):1154-1162. PubMed ID: 30816621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Is ITP a thrombophilic disorder?
    Rodeghiero F
    Am J Hematol; 2016 Jan; 91(1):39-45. PubMed ID: 26547507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune thrombocytopenia with clinical significance in systemic lupus erythematosus: a retrospective cohort study of 90 patients.
    Roussotte M; Gerfaud-Valentin M; Hot A; Audia S; Bonnotte B; Thibault T; Lobbes H; Le Guenno G; Goulabchand R; Cathebras P; Varron L; Dufour JF; Deroux A; Compain C; Baudet A; Karkowski L; Pérard L; Ebbo M; Lega JC; Sève P
    Rheumatology (Oxford); 2022 Aug; 61(9):3627-3639. PubMed ID: 34918048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Thromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis.
    Doobaree IU; Nandigam R; Bennett D; Newland A; Provan D
    Eur J Haematol; 2016 Oct; 97(4):321-30. PubMed ID: 27199203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary immune thrombocytopenia (ITP) treated with romiplostim in routine clinical practice: retrospective study from the United Kingdom ITP Registry.
    Doobaree IU; Newland A; McDonald V; Nandigam R; Mensah L; Leroy S; Seesaghur A; Patel H; Wetten S; Provan D
    Eur J Haematol; 2019 May; 102(5):416-423. PubMed ID: 30758874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Thrombosis in immune thrombocytopenia - current status and future perspectives.
    Swan D; Newland A; Rodeghiero F; Thachil J
    Br J Haematol; 2021 Sep; 194(5):822-834. PubMed ID: 33822358
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment-free remission after thrombopoietin receptor agonist discontinuation in patients with newly diagnosed immune thrombocytopenia: an observational retrospective analysis in real-world clinical practice.
    Iino M; Sakamoto Y; Sato T
    Int J Hematol; 2020 Aug; 112(2):159-168. PubMed ID: 32476083
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-world use of thrombopoietin receptor agonists in older patients with primary immune thrombocytopenia.
    Palandri F; Rossi E; Bartoletti D; Ferretti A; Ruggeri M; Lucchini E; Carrai V; Barcellini W; Patriarca A; Rivolti E; Consoli U; Cantoni S; Oliva EN; Chiurazzi F; Caocci G; Giuffrida G; Borchiellini A; Auteri G; Baldacci E; Carli G; Nicolosi D; Sutto E; Carpenedo M; Cavo M; Mazzucconi MG; Zaja F; De Stefano V; Rodeghiero F; Vianelli N
    Blood; 2021 Aug; 138(7):571-583. PubMed ID: 33889952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic ITP in routine clinical practice in central and Eastern Europe: an analysis of the PLATON study.
    Skopec B; Sninska Z; Tzvetkov N; Ivanushkin V; Björklöf K; Hippenmeyer J; Mihaylov G
    Hematology; 2021 Dec; 26(1):497-502. PubMed ID: 34238136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.